Hyperfine, Inc. · NASDAQ:HYPR
Hyperfine — Investor Presentation (January 2026)
21 slides from Hyperfine's investor presentation, Jan 12, 2026
Slide 1: AI-Powered, Portable Brain MRI: Corporate Investor Deck January 2026
Exhibit 99.2 AI-POWERED, PORTABLE BRAIN MRI The Swoop® Portable MR Imaging System is Driving the Future of Brain Health Corporate Investor Deck – January 2026 The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo is a trademark of Hyperfine, I
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the “Company”) may differ from its expectations, estimates and projections
Slide 3: MRI is the Clinical Gold Standard, But Capacity and Access Are Limited
MRI is the Clinical Gold Standard, But Capacity and Access Are Limited The MRI You Know The MRI You Wish For Significantly less expensive, no High-cost and complex site shielding or siting required. requirements limit access Available at any healthcare facility Need for highly trained No dedicated p
Slide 4: Large Market Potential Bringing MRI to Multiple Sites of Care
Large Market Potential Bringing MRI to Multiple Sites of Care 1 Sizeable and Growing US TAM Through New Sites of Care $1.5B $6B+ $16B+ Outpatient Settings Community Settings Inpatient Settings 2025+ 2026+ 2023+ 2 Emergency departments Urgent care facilities Adult critical care 4,000+ 10,000+ Neurolo
Slide 5: The Swoop System Transforms and Expands the Reach of Brain Imaging
The Swoop System Transforms and Expands the Reach of Brain Imaging Diagnostic Images Captured in Portable, Compact Design Goes Simplified Set Up and Scanning for Directly to the Patient Broad Usability Multiple Sites of Care USING THE SWOOP SYSTEM IMPROVES MRI CAPACITY AND ACCESS WITH MEANINGFUL CLI
Slide 6: Strong Foundation for Commercial Growth
Strong Foundation for Commercial Growth Development, Clinical & Early Compelling Growth Strategy Commercial Expansion Commercial • Next Gen Swoop System Launch ● First Mover Advantage • Outstanding market feedback on Optive AI image quality Hospital Office International • ~200 Issued Patents • Place
Slide 7: Image Quality Approaching Conventional MRI
Image Quality Approaching Conventional MRI 0.064T New Swoop System 1.5 T Conventional MRI Powered by Optive AI Software Sources: T2 images from Swoop system in 2025 and representative image from 1.5T conventional MRI 7 PROPERTY OF HYPERFINE ©2026. All rights reserved.
Slide 8: Image Quality of Next Gen Swoop System to Drive Broad Adoption
FLAIR (Swoop System) FLAIR (High-field 3T) Image Quality of Next Gen Swoop System to Drive Broad Adoption Image Quality Approaching Conventional MRI Case Study of Swoop System vs. High-Field 3T 63-year-old female with history of prior infarct presenting with new-onset headache. Physicians performed
Slide 9: AI-Enabled Imaging Software
AI-Enabled Imaging Software Advanced, AI-driven image reconstruction to ultra-low field MRI—unlocking clearer images at lower field strengths Reduces noise and blur with deep learning, enhances image clarity and consistency, provides sharper anatomical detail to support confident diagnoses at the po
Slide 10: Robust Commercial Growth Strategy Driven By Growth in Business Verticals
Robust Commercial Growth Strategy Driven By Growth in 3 Business Verticals Hospital Business Office Business International Business • Increase access to MRI • Increase revenue & lower cost • New revenue stream • Make MRI available where • Improve patient progress • Improve access to imaging Value re
Slide 11: Hospital Business
Hospital Business • Compelling clinical utility in critical care, emergency triage, neurosurgery and neuro follow up in adults and peds • Strong economic value proposition o Swoop system scans qualify for existing reimbursement (CPT 70551) o Opportunity to increase revenue, cost savings and optimize
Slide 12: Office Business
Office Business • A typical neurologist orders 500–600 MRIs 1,2 annually for neurologic conditions such as headaches, dementia, tumor, MS, surgery follow-up • 90% of private neurology practices don’t have on- 3 site MR imaging • Affordable and appealing, plug-and-play Swoop system o No specialized s
Slide 13: International Business
International Business • Compelling clinical utility transferable globally • Selling primarily into the hospital setting, demonstrated value proposition in remote settings • Optive AI software launch in 10 European languages in Q4’25 • Next generation Swoop system clearance expected in Europe and Ca
Slide 14: Scalable Commercialization with US Direct Sales and Global Distribution Network
Scalable Commercialization with US Direct Sales and Global Distribution Network INSTALLED BASE 1 Over 200 Swoop Systems Globally DIRECT DISTRIBUTORS Dedicated Selling & Implementation Teams (~15 FTE in Total) 10+ Markets (2 FTE in Total) Healthy US Pricing & Recurring Revenue Swoop System Manufactur
Slide 15: Multiples Proof Points and Strong Commercial Outlook from Next Gen Swoop System
Multiples Proof Points and Strong Commercial Outlook from Next Gen Swoop System Since Next Gen System Launch Commercial Outlook o US Hospital Pipeline Converted to Next Gen o Overwhelmingly Positive Feedback on System Image Quality and Radiology Community Ready to Support, Read, and Endorse o Majori
Slide 16: 2025 Preliminary Financial Profile
1 2025 Preliminary Financial Profile Strong Revenue and Cash Burn Performance. Substantial Sequential Improvement 2 REVENUE CASH BURN $5.3 $10.1 -19% +54% $8.1 -27% $3.4 +27% $5.9 -3% $5.7 $2.7 +26% $2.1 1 1 Q1'25 Q2'25 Q3'25 Q4'25 Est. Q1'25 Q2'25 Q3'25 Q4'25 Est. 1) Preliminary, Unaudited Financia
Slide 17: Solid Financial Fundamentals
Solid Financial Fundamentals “Tale of 2 Halves” Revenue and Realizing Operating Leverage Key Takeaways 2 REVENUE AND GROSS MARGIN CASH BURN • Transition to Commercial Stage 2023 2024 2025 Est. Organization in 2025 0.52 45 Q3’25 YTD 49.1% $42.3 • Next Generation Swoop System Gross Margin % 16 Launche
Slide 18: Future Opportunities in New Anatomies, Interventions and Capabilities
FUTURE OPPORTUNITIES IN NEW ANATOMIES, INTERVENTIONS AND CAPABILITIES HYPERFINE PATENTS AND KNOW-HOW ARE WELL POSITIONED TO DELIVER IN MULTIPLE MARKETS WITH ADDITIONAL GROWTH AND VALUE-ADDED SERVICES Future Next Now Mobile for acute care Mobile brain health Expanded sequence Neuro and private practi
Slide 19: Leadership Team With Proven Track Record of Success
Leadership Team With Proven Track Record of Success Maria Brett Hale Tom Rob Chief Administrative Fasciano, PhD Sainz Teisseyre, PhD Officer and Chief President and Chief Chief Operating Chief Regulatory Financial Officer Executive Officer Officer and Quality Officer Edmond Rafael Donnay Chi Nguyen
Slide 20: Swoop System Powered by Optive AI Software
1 Swoop System Powered by Optive AI Software First mover advantage with Commercial in the US hospital and proprietary position (~200 office markets through direct sales patents) across multiple fields of channel use Global footprint through AI-enabled and a leading distributors and partnership with
Slide 21: FAYPERFINE.
FAYPERFINE.